Two recently-published studies of LifeScan‘s OneTouch Verio Flex blood glucose monitoring system showed that the technology is accurate, reliable and linked with improvements in glycemic control, the Johnson & Johnson (NYSE:JNJ) business touted today.
The release comes just days after the healthcare giant revealed that it plans to shut down its Animas insulin pump business and review its LifeScan division.
Get the full story at our sister site, Drug Delivery Business News.
The post J&J’s LifeScan touts studies of OneTouch blood glucose monitoring system appeared first on MassDevice.
from MassDevice http://ift.tt/2xjCSlq
Cap comentari:
Publica un comentari a l'entrada